尔康制药:公司抗心衰药物品种原料药的相关研究已完成
Group 1 - The company has clarified that its core investigational heart failure drug is different from "HK-001" mentioned by investors [2] - The raw material research for the company's heart failure drug has been completed and is publicly listed on the National Medical Products Administration's platform [2] - The bioequivalence (BE) clinical trials for the formulation have been completed, and related work is ongoing [2]